# NCT03301220 (NCT03301220)

> A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03301220
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Janssen Research & Development, LLC
- Conditions: Smoldering Multiple Myeloma
- Interventions: Daratumumab SC: daratumumab + rHuPH20
- Enrollment: 390
- Primary outcome: Progression-Free Survival (PFS) as Assessed by the Independent Review Committee (IRC)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct03301220